MDACC Study No:2013-0161 ( NCT No: NCT02013167)
Title:A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Principal Investigator:Hagop Kantarjian
Treatment Agent:Blinatumomab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if and how long
blinatumomab may be able to help control B-precursor, relapsed or refractory
Ph- ALL compared to standard-of-care chemotherapy treatments. The safety of
blinatumomab will also be compared to standard-of-care chemotherapy.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:Blinatumomab
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Amgen
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults